ProKidney Corp
PROK
查看详细走势图
2.530USD
-0.040-1.56%
收盘 12/26, 16:00（美东）报价延迟15分钟
344.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.56%
5天
+6.75%
1月
+19.34%
6月
+278.35%
今年开始到现在
+49.70%
1年
+48.82%
查看详细走势图
TradingKey ProKidney Corp股票评分
单位: USD 更新时间: 2025-12-26操作建议
ProKidney Corp当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名165/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.83。中期看，股价处于平稳状态。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
ProKidney Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
5.833
目标均价
+148.23%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ProKidney Corp亮点
亮点风险
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
业绩增长期
公司处于发展阶段，最新年度总收入76.00K美元
估值合理
公司最新PE估值-4.61，处于3年历史合理位
机构减仓
最新机构持股38.60M股，环比减少29.29%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值10.21K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.16
ProKidney Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ProKidney Corp简介
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
公司代码PROK
公司ProKidney Corp
CEOCulleton (Bruce)
网址https://prokidney.com/
常见问题
ProKidney Corp(PROK)的当前股价是多少？
ProKidney Corp(PROK)的当前股价是 2.530。
ProKidney Corp的股票代码是什么？
ProKidney Corp的股票代码是PROK。
ProKidney Corp股票的52周最高点是多少？
ProKidney Corp股票的52周最高点是7.130。
ProKidney Corp股票的52周最低点是多少？
ProKidney Corp股票的52周最低点是0.460。
ProKidney Corp的市值是多少？
ProKidney Corp的市值是344.02M。
ProKidney Corp的净利润是多少？
ProKidney Corp的净利润为-61.19M。
现在ProKidney Corp(PROK)的股票是买入、持有还是卖出？
根据分析师评级，ProKidney Corp(PROK)的总体评级为买入，目标价格为5.833。
ProKidney Corp(PROK)股票的每股收益（EPS TTM）是多少
ProKidney Corp(PROK)股票的每股收益（EPS TTM）是-0.549。
相关品种
